Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 12.5 Billion KRW | 67.37% |
| 2022 | 7.46 Billion KRW | 1045.76% |
| 2021 | 651.83 Million KRW | -90.55% |
| 2020 | 6.9 Billion KRW | -26.69% |
| 2019 | 9.41 Billion KRW | 411.48% |
| 2018 | 1.84 Billion KRW | -64.91% |
| 2017 | 5.24 Billion KRW | -3.77% |
| 2016 | 5.44 Billion KRW | 738.77% |
| 2015 | 649.74 Million KRW | 62.44% |
| 2014 | 400 Million KRW | -75.0% |
| 2013 | 1.6 Billion KRW | -78.68% |
| 2012 | 7.5 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 10.04 Billion KRW | -19.64% |
| 2024 Q1 | 12.5 Billion KRW | 0.0% |
| 2023 Q3 | 12.5 Billion KRW | 56.87% |
| 2023 Q4 | 12.5 Billion KRW | 0.0% |
| 2023 Q1 | 7.96 Billion KRW | 6.69% |
| 2023 FY | 12.5 Billion KRW | 67.37% |
| 2023 Q2 | 7.96 Billion KRW | 0.0% |
| 2022 Q3 | 5 Billion KRW | 150.0% |
| 2022 FY | 7.46 Billion KRW | 1045.76% |
| 2022 Q4 | 7.46 Billion KRW | 49.37% |
| 2022 Q2 | 2 Billion KRW | 152.71% |
| 2022 Q1 | 791.4 Million KRW | 21.41% |
| 2021 Q1 | 543 Million KRW | -92.65% |
| 2021 Q4 | 651.83 Million KRW | -1.92% |
| 2021 FY | 651.83 Million KRW | -90.55% |
| 2021 Q3 | 664.61 Million KRW | 9.84% |
| 2021 Q2 | 605.05 Million KRW | 11.43% |
| 2020 FY | 6.9 Billion KRW | -26.69% |
| 2020 Q2 | 7.63 Billion KRW | -23.27% |
| 2020 Q3 | 7.55 Billion KRW | -1.07% |
| 2020 Q4 | 7.38 Billion KRW | -2.23% |
| 2020 Q1 | 9.95 Billion KRW | -0.64% |
| 2019 Q1 | 1.91 Billion KRW | 4.15% |
| 2019 Q2 | 9.68 Billion KRW | 405.31% |
| 2019 Q3 | 9.71 Billion KRW | 0.34% |
| 2019 FY | 9.41 Billion KRW | 411.48% |
| 2019 Q4 | 10.02 Billion KRW | 3.12% |
| 2018 Q1 | 5.15 Billion KRW | -1.75% |
| 2018 FY | 1.84 Billion KRW | -64.91% |
| 2018 Q4 | 1.84 Billion KRW | -89.26% |
| 2018 Q3 | 17.13 Billion KRW | 2.44% |
| 2018 Q2 | 16.72 Billion KRW | 224.54% |
| 2017 FY | 5.24 Billion KRW | -3.77% |
| 2017 Q4 | 5.24 Billion KRW | -1.72% |
| 2017 Q3 | 5.33 Billion KRW | -5.18% |
| 2017 Q2 | 5.62 Billion KRW | -1.6% |
| 2017 Q1 | 5.71 Billion KRW | 4.94% |
| 2016 Q2 | 5.54 Billion KRW | 825.33% |
| 2016 FY | 5.44 Billion KRW | 738.77% |
| 2016 Q3 | 5.49 Billion KRW | -0.9% |
| 2016 Q4 | 5.44 Billion KRW | -0.91% |
| 2016 Q1 | 599.76 Million KRW | -7.69% |
| 2015 Q1 | 1.02 Billion KRW | 156.17% |
| 2015 Q4 | 649.74 Million KRW | -7.14% |
| 2015 Q3 | 699.72 Million KRW | -17.65% |
| 2015 Q2 | 849.7 Million KRW | -17.08% |
| 2015 FY | 649.74 Million KRW | 62.44% |
| 2014 Q2 | 4.73 Billion KRW | 286.61% |
| 2014 Q3 | 625 Million KRW | -86.8% |
| 2014 Q4 | 400 Million KRW | -36.0% |
| 2014 Q1 | 1.22 Billion KRW | -23.44% |
| 2014 FY | 400 Million KRW | -75.0% |
| 2013 FY | 1.6 Billion KRW | -78.68% |
| 2013 Q4 | 1.6 Billion KRW | -8.57% |
| 2013 Q3 | 1.75 Billion KRW | -74.02% |
| 2013 Q2 | 6.73 Billion KRW | 149.02% |
| 2013 Q1 | 2.7 Billion KRW | -63.96% |
| 2012 FY | 7.5 Billion KRW | 0.0% |
| 2012 Q4 | 7.5 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| HLB Co., Ltd. | 17.93 Billion KRW | 30.297% |
| iNtRON Biotechnology, Inc. | 258.29 Million KRW | -4739.43% |
| BINEX Co., Ltd. | 5.57 Billion KRW | -124.08% |
| Anterogen.Co.,Ltd. | - KRW | -Infinity% |
| MEDIPOST Co., Ltd. | 6.99 Billion KRW | -78.701% |
| CrystalGenomics, Inc. | 29.88 Billion USD | 58.179% |
| Helixmith Co., Ltd | 151.68 Million KRW | -8141.034% |
| Chabiotech Co.,Ltd. | 95.06 Billion KRW | 86.851% |
| Medy-Tox Inc. | 1.22 Billion KRW | -919.707% |
| Peptron, Inc. | 4.5 Billion KRW | -177.778% |
| Amicogen, Inc. | 70.65 Billion KRW | 82.308% |
| Genexine, Inc. | 22.68 Billion KRW | 44.889% |
| HLB Therapeutics Co.,Ltd. | 1.84 Billion KRW | -579.278% |
| LegoChem Biosciences, Inc. | 528.37 Million KRW | -2265.754% |
| ALTEOGEN Inc. | 1.24 Billion KRW | -900.595% |
| PharmaResearch Co., Ltd. | 970.71 Million KRW | -1187.708% |
| SillaJen, Inc. | 8.13 Billion KRW | -53.641% |
| JETEMA, Co., Ltd. | 60 Billion KRW | 79.167% |
| OliX Pharmaceuticals,Inc | 35.36 Billion KRW | 64.651% |
| Genomictree Inc. | 97.51 Million KRW | -12718.454% |
| MedPacto, Inc. | 1.68 Billion KRW | -640.984% |
| D&D Pharmatech | 5.12 Billion KRW | -144.111% |
| EASY BIO,Inc. | 30 Billion KRW | 58.333% |
| GI Innovation, Inc. | 2.9 Billion KRW | -330.44% |